Cargando…

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

For patients with optimally treated chronic myeloid leukemia (CML), discontinuation of tyrosine kinase inhibitor (TKI) therapy can lead to treatment-free remission. In previous trials, TKI discontinuation has been associated with increased musculoskeletal pain in some patients (“withdrawal syndrome”...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flynn, Kathryn E., Atallah, Ehab, Lin, Li, Shah, Neil P., Silver, Richard T., Larson, Richard A., Pinilla-Ibarz, Javier, Thompson, James E., Oehler, Vivian G., Radich, Jerald P., Kota, Vamsi, Mauro, Michael J., Schiffer, Charles A., Cortes, Jorge, Weinfurt, Kevin P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Chronic Myeloid Leukemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614525/ https://www.ncbi.nlm.nih.gov/pubmed/35511672 http://dx.doi.org/10.3324/haematol.2021.280377

Ejemplares similares

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

CML-384 Immunological Response to SARS-CoV-2 After Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients – A Prospective Study
por: Galvis, Marisol Miranda, et al.
Publicado: (2022)

CML-005: Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with a Donor and Recipient with SARS-CoV-2 Infection
por: Ali, Gadallah, et al.
Publicado: (2021)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
por: Harrington, Patrick, et al.
Publicado: (2023)

CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries
por: Matsuzaki, Mika, et al.
Publicado: (2023)

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
por: Shanmuganathan, Naranie, et al.
Publicado: (2023)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
por: Zhang, Hualei, et al.
Publicado: (2022)

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
por: Dulucq, Stéphanie, et al.
Publicado: (2022)

IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
por: Fiordi, Benedetta, et al.
Publicado: (2023)

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)
por: Bonifacio, Massimiliano, et al.
Publicado: (2020)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia
por: Atallah, Ehab, et al.
Publicado: (2018)

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia
por: Claudiani, Simone, et al.
Publicado: (2020)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience
por: Pagnano, Katia B, et al.
Publicado: (2020)

TKI safety
por: Hjorth-Hansen, Henrik
Publicado: (2019)

Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019)

NGS in CML - New standard diagnostic procedure?
por: Branford, Susan, et al.
Publicado: (2019)

Treatment-Free Remission: the New Goal in CML Therapy
por: Atallah, Ehab, et al.
Publicado: (2021)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study
por: Pagnano, Katia B, et al.
Publicado: (2021)

AML-168: The Assessment of COVID-19 Evolution in Patients with Oncological Diseases Admitted in an Intensive Care Unit of One Romanian Center
por: Popov, Viola Maria, et al.
Publicado: (2021)

AML-145: Outcomes of Induction Therapy in Patients with Acute Myeloid Leukemia During Covid-19 Pandemic: A Retrospective Study from a Tertiary Care Cancer Centre
por: Iqbal, Asif, et al.
Publicado: (2021)

AML-355: Incidence and Severity of COVID-19 among Inpatients with Hematologic Malignancies
por: Wozniaki, Natalia, et al.
Publicado: (2021)

AML-075: Converting In-Person Research Procedures to a Virtual Platform During the COVID-19 Pandemic in Newly Diagnosed Acute Myeloid Leukemia Patients
por: Tinsley, Sara, et al.
Publicado: (2021)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients
por: Fechio, Leonardo, et al.
Publicado: (2021)

Impact of the Covid-19 Pandemic on Quality of Life of Patients with CML
por: Wysoglad, Hubert, et al.
Publicado: (2021)

Humoral Immunity and Adverse Events after Vaccination Against COVID-19 By a Vector Based Vaccine Sputnik V in Patients with Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina Yu., et al.
Publicado: (2021)

Results of a Single Center Survey on Vaccination Against COVID-19 in Patients with Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina Yu., et al.
Publicado: (2021)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
por: Zhang, Weiguo, et al.
Publicado: (2022)

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4i4mni5klqolsaoqh7rmvr3ig7